Mesenchymal Stem Cells Market With Top 20 Countries data Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026…

Coherent Market Insights announced that its published an exclusive report namely Global Mesenchymal Stem Cells Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Mesenchymal Stem Cells Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

Get PDF Brochure Of This Report Here @ https://www.coherentmarketinsights.com/insight/request-pdf/720

The report presents an overview of Mesenchymal Stem Cells Market consist of objectives study and definition of Mesenchymal Stem Cells. The next section focuses on market size, region-wise Mesenchymal Stem Cells growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Mesenchymal Stem Cells Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

Following market aspects are enfolded in Global Mesenchymal Stem Cells Market Report:

A wide summarization of the Global Mesenchymal Stem Cells Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Mesenchymal Stem Cells Market. Analysis of company profiles of Top major players functioning in the market.

Mesenchymal Stem Cells Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Mesenchymal Stem Cells Market players in detail. Mesenchymal Stem Cells Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Key questions answered in Report:-

Mesenchymal Stem Cells Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Mesenchymal Stem Cells, Guidelines Overview and Upcoming Trends Forecast till 2027 Mesenchymal Stem Cells Market Top Companies Sales, Price, Revenue and Market Share Outlook Mesenchymal Stem Cells Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Mesenchymal Stem Cells by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Mesenchymal Stem Cells Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

****Stay Home. Stay Safe****

Originally posted here:

Mesenchymal Stem Cells Market With Top 20 Countries data Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026...

Read more
Global Mesenchymal Stem Cells Market is expected to register the significant growth over the forecast period 2020-2026 – Market Research Correspondent

Global Marketers offers newly published research report titled, Mesenchymal Stem Cells Market .This report focuses on delivering the up-to-date and latest growth opportunities, 360-degree market overview, and statistical data of Mesenchymal Stem Cells industry. The report highlights industry overview, growth trajectory, market dynamics, market share analyzed in detail this report. It furthermore gives a total synopsis of the market over the globe, including definitions, and applications. Moreover, the improvement plans and policies concerning the market have been discussed in the statistical surveying report, alongside the cost structures and production processes.

Get Free Sample copy @ https://www.globalmarketers.biz/report/life-sciences/global-mesenchymal-stem-cells-market-report-2019,-competitive-landscape,-trends-and-opportunities/135868#request_sample

The most significant players coated in global Mesenchymal Stem Cells Market report:

MesoblastBio-TechneIrvine ScientificMiltenyi BiotecPromoCell GmbHLonzaAxol BioscienceThermo FisherBiological IndustriesSTEMCELL Technologies

The research report also studied the key players operating in the global Mesenchymal Stem Cells Market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the prediction period. This research report also includes the list of planned initiatives that clearly explain the achievements of the Mesenchymal Stem Cells companies in the recent past.

Global Mesenchymal Stem Cells Market Regions Analysis:

Regional analysis is a highly all-inclusive part of this report. The geographical analysis of the global Mesenchymal Stem Cells Market has been showed in four major regions, namely the Asia Pacific, North America, Europe, and the rest of the world containing Latin America and the Middle East and Africa.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.globalmarketers.biz/discount_inquiry/discount/135868

The competitive landscape of the Mesenchymal Stem Cells market is described in terms of the players and their statistics. The research on the Mesenchymal Stem Cells will be applicable to investors, business owners, industry experts, and various c level peoples. The report also creates a clear picture of the various factors that will drive the Mesenchymal Stem Cells Market in the years to come. This report offers a SWOT analysis of the global market.

The Type Coverage in the Market are:

MSC-ATMSC-UCMSC-BMOthers

The Application Coverage in the Market are:

Cell-based Screening AssaysGene Therapy and TransplantationCell Differentiation and Gene Regulation

The Mesenchymal Stem Cells market analysts and researchers have done wide analysis of the global Mesenchymal Stem Cells industry with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided exact market data and worthwhile recommendations with an aim to help the key players to gain an insight into the overall current and future market scenario.

The study analyses the following key business aspects:

Table ofContents

Global Mesenchymal Stem Cells Market Research Report 2019-2026

Chapter 1 Mesenchymal Stem Cells Market Overview

Chapter 2 Global Economic Impact on Mesenchymal Stem Cells Industry

Chapter 3 Global Market Competition by Key Vendors

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Production, Revenue (Value), Price Trend by Type

Chapter 6 Global Mesenchymal Stem Cells Market Analysis by Application

Chapter 7 Manufacturing Cost Analysis of Mesenchymal Stem Cells Market

Chapter 8 Marketing Strategy Analysis, Traders

Chapter 9 Mesenchymal Stem Cells Market Factors Analysis

Chapter 10 Global Mesenchymal Stem Cells Market Forecast up to 2026

Get Full Report With Complete TOC @ https://www.globalmarketers.biz/report/life-sciences/global-mesenchymal-stem-cells-market-report-2019,-competitive-landscape,-trends-and-opportunities/135868#table_of_contents

Follow this link:

Global Mesenchymal Stem Cells Market is expected to register the significant growth over the forecast period 2020-2026 - Market Research Correspondent

Read more
Stem Cells Cryopreservation Equipments Market to grow significantly in future | Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment…

The Global Stem Cells Cryopreservation Equipments Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2020-2025). The assessment provides a 360 view and insights, outlining the key outcomes of the industry, current scenario witnesses a slowdown and study aims to unique strategies followed by key players. These insights also help the business decision-makers to formulate better business plans and make informed decisions for improved profitability. In addition, the study helps venture or private players in understanding the companies more precisely to make better informed decisions. Some of the key players in the Global Stem Cells Cryopreservation Equipments market are Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment,Sichuan Mountain Vertical,Qingdao Beol.

Whats keeping Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment,Sichuan Mountain Vertical,Qingdao Beol. Ahead in the Market? Benchmark yourself with strategic steps and conclusions recently published by HTF MI. Analyze COVID impact on overall Industry.

Get Sample Pdf with Latest Figures @:https://www.htfmarketreport.com/sample-report/0-1318817.0

The Major Players Covered in this Report: Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment,Sichuan Mountain Vertical,Qingdao Beol.

By type, the market is split as: Liquid Phase,Vapor PhaseBy the end users/application, sub-segments are: Cord Blood Stem Cells Cryopreservation,Other Stem Cells Cryopreservation

Regional Analysis for Stem Cells Cryopreservation Equipments Market:North America, Europe, Asia-Pacific etc

For Consumer Centric Market, Survey Analysis can be included as part of customization which consider demographic factor such as Age, Gender, Occupation, Income Level or Education while gathering data. (if applicable)

Consumer Traits (If Applicable)Buying patterns (e.g. comfort & convenience, economical, pride)Buying behavior (e.g. seasonal, usage rate)Lifestyle (e.g. health conscious, family orientated, community active)Expectations (e.g. service, quality, risk, influence)

The Global Stem Cells Cryopreservation Equipments Market study covers current status, % share, future patterns, development rate, SWOT examination, sales channels, to anticipate growth scenarios for years 2020-2025. It aims to recommend analysis of the market with regards to growth trends, prospects, and players contribution in the market development. The report size market by 5 major regions, known as, North America, Europe, Asia Pacific (includes Asia & Oceania seperately), Middle East and Africa (MEA), and Latin America.

If you need any specific requirement Ask to our Expert @https://www.htfmarketreport.com/enquiry-before-buy/0-1318817.0

The Stem Cells Cryopreservation Equipments market factors described in this report are:-Key Strategic Developments in Global Stem Cells Cryopreservation Equipments Market:The research includes the key strategic activities such as R&D plans, M&A completed, agreements, new launches, collaborations, partnerships & (JV) Joint ventures, and regional growth of the key competitors operating in the market at global and regional scale.

Key Market Features in Global Stem Cells Cryopreservation Equipments Market:The report highlights Stem Cells Cryopreservation Equipments market features, including revenue, weighted average regional price, capacity utilization rate, production rate, gross margins, consumption, import & export, supply & demand, cost bench-marking, market share, CAGR, and gross margin.

Analytical Market Highlights & ApproachThe Global Stem Cells Cryopreservation Equipments Market report provides the rigorously studied and evaluated data of the top industry players and their scope in the market by means of several analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, SWOT analysis, and ROI analysis have been practiced reviewing the growth of the key players operating in the market.

Table of Contents :Global Stem Cells Cryopreservation Equipments Market Study Coverage:It includes major manufacturers, emerging players growth story, major business segments of Global Stem Cells Cryopreservation Equipments market, years considered, and research objectives. Additionally, segmentation on the basis of the type of product, application and technology.

Global Stem Cells Cryopreservation Equipments Market Executive SummaryIt gives a summary of overall studies, growth rate, available market, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.Global Stem Cells Cryopreservation Equipments Market Production by RegionGlobal Stem Cells Cryopreservation Equipments Market Profile of ManufacturersPlayers are studied on the basis of SWOT, their products, production, value, financials, and other vital factors.

For Complete table of Contents please click here @https://www.htfmarketreport.com/reports/0-1318817.0

Key Points Covered in Stem Cells Cryopreservation Equipments Market Report:Stem Cells Cryopreservation Equipments Overview, Definition and ClassificationMarket drivers and barriersStem Cells Cryopreservation Equipments Market Competition by ManufacturersStem Cells Cryopreservation Equipments Capacity, Production, Revenue (Value) by Region (2019-2025)Stem Cells Cryopreservation Equipments Supply (Production), Consumption, Export, Import by Region (2019-2025)Stem Cells Cryopreservation Equipments Production, Revenue (Value), Price Trend by TypeStem Cells Cryopreservation Equipments Market Analysis by ApplicationStem Cells Cryopreservation Equipments Manufacturers Profiles/AnalysisStem Cells Cryopreservation Equipments Manufacturing Cost AnalysisIndustrial/Supply Chain Analysis, Sourcing Strategy and Downstream BuyersMarketing Strategy by Key Manufacturers/Players, Connected Distributors/TradersStandardization, Regulatory and collaborative initiativesIndustry road map and value chainMarket Effect Factors Analysis

Buy Latest Version of Report Available Now at Discounted Pricing @https://www.htfmarketreport.com/buy-now?format=1&report=0

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, LATAM, Europe or Southeast Asia or Just Eastern Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.comConnect with us atLinkedIn|Facebook|Twitter

See the original post:

Stem Cells Cryopreservation Equipments Market to grow significantly in future | Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment...

Read more
Stem Cell Therapy Market Latest Trends, Development, Revenue, Demand And Forecast To 2022 – Market Research Correspondent

Stem Cell Therapy Market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022.

The global stem cell therapy market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the stem cell therapy market.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10325644

KEY BENEFITS OF THE REPORT:Deeper understanding of the strategies adopted by the key players in this market to stay competitiveGranular analysis about the growth map of the market during the next five yearsComprehensive analysis of the key market players and their market share

KEY PREMIUM INDUSTRY INSIGHTS:The increasing government initiatives and funding from various organizations, the increased spending on research and development, rapid technological advancement in genomics, and the rising awareness about the stem cell therapy are some of the factors fuelling the growth of the stem cell therapy market.

Other factors, such as the robust product pipelines and increasing approval of the new clinical trials are fuelling the growth of the stem cell therapy market further.However, improper infrastructure, insufficient storage systems, and ethical problems are the major restraints for the stem cell therapy market.

MARKET SEGMENTATION:This report analyzes the stem cell therapy market by the following segments:

Stem Cell Therapy Market, by TreatmentsAllogeneic Stem Cell TherapyAutologous Stem Cell TherapyStem Cell Therapy Market, by ApplicationsOncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, by End-usersHospitalsAmbulatory Surgical Centers

Request For Full Report:https://www.kennethresearch.com/sample-request-10325644

KEY MARKET PLAYERS:Key players in the stem cell therapy market include:

Vericel Corporation.Stem Cells, Inc.Mesoblast, Ltd.Gamida CellOsiris Therapeutics, Inc.Chiesi Farmaceutici S.p.AReNeuron Group, plc

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

See the original post:

Stem Cell Therapy Market Latest Trends, Development, Revenue, Demand And Forecast To 2022 - Market Research Correspondent

Read more
FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL – Pharmacy Times

FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL

A humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, tafasitamab-cxix received accelerated approval based on overall response rate (ORR). Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Globally, DLBCL is the most common type of non-Hodgkin lymphoma in adults. The aggressive disease is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs, and about 1 in 3 patients do not respond to initial therapy or relapsing thereafter.In the United States, approximately 10,000 patients are diagnosed with relapsed or refractory DLBCL who are not eligible for ASCT, each year.

The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of tafasitamab-cxix in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL. Results from the study showed an ORR of 55% (primary endpoint), including a complete response (CR) rate of 37%, and a partial response rate (PR) of 18%. The median duration of response (mDOR) was 21.7 months (key secondary endpoint).

Warnings and precautions for tafasitamab-cxix included infusion-related reactions (6%), serious or severe myelosuppression including neutropenia (50%), thrombocytopenia (18%), and anemia (7%); infections (73%), and embryo-fetal toxicity. Neutropenia led to treatment discontinuation in 3.7% of patients. The most common adverse reactions ( 20%) were neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.

The FDA previously granted Fast Track and Breakthrough Therapy Designation for the tafasitamab-cxix and lenalidomide combination in treatment of relapsed or refractory DLBCL. FDA.

Tafasitamab-cxix is expected to be commercially available in the United States shortly, according to MorphoSys and Incyte, which plan to co-commercialize this therapy in the US. Incyte has exclusive commercialization rights outside the US.

REFERENCE

FDA Approves Monjuvi(tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [news release]. Planegg & Munich, Germany, and Wilmington, DE; July 31, 2020: MorphoSys and Incyte.https://www.businesswire.com/news/home/20200731005497/en.

Read more:

FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL - Pharmacy Times

Read more
Meso Numismatics Update on 2nd Transaction with Global Stem Cells – GlobeNewswire

LAS VEGAS, NV, July 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has recently successfully made the second payment ($75,000) to Global Stem Cells Group on time as per the companys LOI amendment dated April 22, 2020.

We are excited about the pending acquisition of Global Stem Cells Group, said David Christensen, CEO and President of Meso Numismatics, Inc. We are extremely optimistic about the opportunities that Stem Cell Biotechnology and the future that Regenerative Medicine can offer the world.

This press release should be read in conjunction with the all other filings on http://www.sec.gov

For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company's breadth of business experience and technology team, the Company will continue to help companies grow.

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words plan, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact:Investor.relations@mssvinc.comTelephone: (800) 956-3935

Excerpt from:

Meso Numismatics Update on 2nd Transaction with Global Stem Cells - GlobeNewswire

Read more
A breakthrough: Stem cell therapy cures Covid-19 The Manila Times – The Manila Times

SIX patients who were suffering from the acute coronavirus disease 2019 (Covid-19) were cured through the stem cell technology using blood from preserved umbilical cords.

The revolutionary method of curing the dreaded virus, which originated in China and has spread worldwide, was announced by The Medical City (TMC) hospital in Pasig City.

Health Secretary Francisco Duque 3rd was informed of the breakthrough in treating the pandemic illness through a letter sent by Dr. Eugenio F. Ramos, TMC president and chief executive officer, on Thursday, July 23.

Our government, particularly the Department of Health, can take pride in the fact that the Philippines is not behind at all in innovative practice in medicine, said Ramos in his letter to Duque.

The TMC has been experimenting with stem cell therapy since 2015 through its Institute of Personalized Molecular Medicines stem cell program.

The stem cell experiment was made on seven Covid-19 patients who were so ill they were about to be intubated.

Intubation means inserting a tube into the patients mouth that reaches the trachea to allow him/her to breathe through a lung machine.

Six of the seven patients had recovered, the TMC said; one was so ill he died during the procedure.

As I told you this morning, we would have wanted to complete at least 10 Covid-19 cases before informing you, but it might be taken against us if we kept this knowledge from the public too long while patients are dying and no single drug seems to work, Dr. Ramos told Duque.

Ramos simplified for the public how the stem cell therapy works:

Stem cells are very young cells from the body that can be differentiated into whatever cell lines (lung, heart, kidney, liver, skin, etc.) that the body needs when it needs them, e.g., when an organ is injured or deteriorates. Stem cells can be triggered or infused to do [repair] work.

In severe Covid-19 cases, what triggers a cascade of inflammatory cells (called cytokines) is the injury caused by the virus. The lungs, in particular, become inflamed and the respiratory function rapidly deteriorates leading to death.

Before the cascade happens in which case the patient is in a severe condition probably requiring intubation the infusion of mesenchymal stem cells collected [from] the umbilical cord and grown in [the regenerative medicine laboratory of TMC into the patients veins, takes place.

A total of four infusions are given over a short period of a few days. These messenchymal stem cells rally the cells in the lungs to fight the cytokines.

In short, the stem cells from the umbilical cord produce new cells to replace those damaged by the virus in the lungs, leading to the patients recovery.

The umbilical cord is rich in nutrients to rebuild destroyed tissues, according to Ramos.

TMCs stem cell program also makes use of bone marrow taken from a patients spine to cure cancer.

But the bone marrow stem cell is also used to delay the aging process in elderly patients.

TMC had the most number of bone marrow transplantation for blood cancers, with more than 90 percent survival rate, said Dr. Ramos.

Since 2015, a total of 112 patients have enrolled in TMCs regenerative medicine program.

Of the total, 57 percent were cancer patients and 43 percent were non-cancer patients, said TMCs Dr. Michelle Joy Baldorado-de Vera.

Oncologists (doctors who specialize in cancer) are part of the regenerative medicine program Alan Olavere, Marina Chua-Tan and Josephine Tolentino.

Other members are hematologists (blood doctors) Norma Ona and Alma Calavera, neurologists John Tiongson and Marc Joseph Buensalido, and immunologist Michelle de Vera.

Dr. Sam Bernal, a Filipino American who grew up in the United States, is a consultant to the program.

Bernal is a molecular scientist and an oncologist who has been into stem cell technology for decades.

He was part of the foreign group that was tapped by the government for technology transfer.

Former Health secretary Alfredo Bengzon, who is a part owner of TMC, engaged Bernal to pioneer stem cell therapy in the country.

TMC has had foreign patients who underwent stem cell therapy, but refuses to disclose their number.

As is the norm among Filipinos who have the crab mentality, TMCs stem cell program has been criticized by fellow doctors.

Weve been defending the program from the outset, said Dr. Ramos.

But its not only TMC that has been into stem cell therapy; the other hospitals are the Makati Medical Center and the governments National Kidney and Transplant Institute.

Here is the original post:

A breakthrough: Stem cell therapy cures Covid-19 The Manila Times - The Manila Times

Read more
AlloVir raises $276M IPO to run broad cell therapy program – FierceBiotech

AlloVir has raised $276 million in an upsized IPO to fund development of allogeneic T-cell treatments for viral diseases. The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.

Massachusetts-based AlloVir generates off-the-shelf virus-specific T cells in donors before stimulating their peripheral blood mononuclear cells to selectively activate and expand the therapeutic cells. By giving patients T cells that partially match their HLA subtype, AlloVir thinks it can kill virus infected cells without harming healthy cells or causing graft-versus-host disease.

Viralym-M is the most advanced manifestation of the approach. Baylor College of Medicine has taken the treatment for five common viruses through phase 2, setting AlloVir up to push the drug toward approval while generating clinical proof-of-concept data in other indications.

AlloVir plans to spend $98 million to take Viralym-M through phase 3 trials in immunocompromised patients post allogeneic hematopoietic stem cell transplant (HSCT) who have complications linked to hemorrhagic cystitis, cytomegalovirus or adenovirus. The phase 2 linked adenovirus Viralym-M to a 93% clinical response rate in HSCT patients with one or more treatment-refractory infections.

The size of the IPO means AlloVir has enough money to pursue other opportunities. In addition to the three phase 3 trials, AlloVir plans to start three phase 2 trials to test Viralym-M in the prevention of multi-virus infections in HSCT patients, and the treatment of BK and cytomegalovirus in kidney and solid organ transplant recipients, respectively.

AlloVir has set aside $83 million for the phase 2 program, leaving it with cash to spend on two other assets. A second cell therapy, ALVR106, is due to enter the clinic in autologous and allogeneic HSCT patients with respiratory viral diseases in the fourth quarter. AlloVir has earmarked $56 million for work on ALVR106.

A further $33 million will go toward a phase 1/2 trial of AlloVirs COVID-19 prospect. AlloVir joined the race to develop a COVID-19 treatment in March, teaming up with Baylor College of Medicine to create an off-the-shelf cell therapy against SARS-CoV-2 and other coronaviruses. The resulting drug, ALVR109, is made of CD4+ and CD8+ virus-specific T cells generated from healthy donors.

Baylor filed an IND for ALVR109 in June, only for FDA to hit it with a clinical hold earlier this month amid safety concerns related to the quality of ancillary reagents unique to ALVR109. Despite the setback, AlloVir still expects the trial to get underway this year and deliver top-line data in 2021.

See original here:

AlloVir raises $276M IPO to run broad cell therapy program - FierceBiotech

Read more
Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases – OncLive

An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib (Copiktra) is effective at reducing lung inflammation in patients with severe novel coronavirus 2019 (COVID-19), thereby decreasing incidences of mechanical ventilation and death in these patients.1,2

Investigators theorize that the agent will not only work to reduce inflammation and pulmonary edema, but could also potentially decrease duration of viremia and prompt a response from immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies that could in turn respond to SARS-Cov-2 spike proteins.

The increase in proteins can lead to a cytokine storm, resulting in severe pneumonitis and acute respiratory distress syndrome (ARDS), and can be fatal.1 Investigators hope to reduce the incidence rate of death or mechanical ventilation intervention, which is 40%, to 15% with the use of duvelisib.

Duvelisibs use in COVID-19 comes not from its anti-cancer properties, but its activity in the immune system. Particularly, we found that it can enhance the growth and expansion of T-cells that retain anti-cancer activity, principal study investigator Edmund K. Waller, MD, PhD, a professor in the Departments of Medicine, Pathology, and Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Center for Stem Cell Processing and Apheresis Emory University Hospital, said in an interview with OncLive. Results from clinical trials in patients with lymphoma show that these patients had lower levels of cytokinesthe inflammatory proteins we believe are a part of COVID-19 pathologywhen theyve been treated with duvelisib compared with other anticancer therapies.

In September 2018, the FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Waller added that duvelisib may help T cells grow and potentially fight COVID-19, while simultaneously modulating the inflammation that could lead to fluid accumulation in patients lungs.

In the study, duvelisib will be administered to patients with COVID-19 over the course of 2 weeks, and investigators will evaluate the agents efficacy in not only reducing the need for mechanical ventilation and the risk of death within 30 days of treatment.

Additional end points include the need for high-flow oxygen devices, supplemental oxygen, and hospitalization with or without ongoing medical care. The targeted enrollment is 80 adults whose ages are 18 years and older who have been confirmed to have severe COVID-19 symptoms, such as pneumonia and difficulty breathing. Patients will then be randomized to either duvelisib (n = 40) or placebo (n = 40). Waller said he hopes to determine whether or not the agent will be effective in managing the virus to prevent patients from being admitted to the intensive care unit. Duvelisib, he added, could provide a valuable third line of defense after the infection has been established.

In a preclinical pharmacology setting, duvelisib was shown to be highly potent, with investigators noting a whole blood IC50 of 0.36 nM for delta subunit inhibition and whole blood IC50 of 19.6nM for gamma subunit inhibition. The agent was shown to double T cells in both patients with CLL, as well as healthy volunteers from 40 nM to 0.4 mM over 9 to 14 days.

Should the study results be positive, Waller said that the data warrant a need for a larger, multicenter study to further confirm the findings. Even in the event of a smaller, but still significant reduction by one-third or more of patients, the research could be expanded to include hundreds of patients with severe COVID-19, he said.

This is a challenging time, concluded Waller. There are more [factors about this virus] that we dont know than we do know. We have to be cautious as new data become available [to ensure] that its rigorously looked at in order to change medical practices based on solid clinical data. Our study is small, and I wont say that it will change clinical practice, but hopefully its a step towards finding better ways to treat these patients.

The rest is here:

Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases - OncLive

Read more
CAR-T Safe, Active in Hodgkin Lymphoma – MedPage Today

A majority of patients with relapsed/refractory Hodgkin lymphoma responded to CD30-targeted chimeric antigen receptor (CAR) T-cell therapy, which caused no significant toxicity, a preliminary clinical study showed.

Overall, 23 of 37 (62%) evaluable patients had objective responses. The response rate increased to 72% when limited to 32 patients who received fludarabine, 19 of whom achieved complete responses.

The most common grade 3 adverse events were hematologic. No patient had grade >1 cytokine release syndrome (CRS), and no neurologic toxicity occurred, Barbara Savoldo, MD, PhD, of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center in Chapel Hill, and co-authors from UNC and Baylor College of Medicine in Houston reported in the Journal of Clinical Oncology.

"This is particularly exciting because the majority of these patients had lymphomas that had not responded well to other new therapies," said Savoldo. "This treatment showed remarkable antitumor activity without significant toxicity, and we think it should be considered for patients in earlier stages of refractory/relapsing Hodgkin lymphoma."

The vast majority of patients with Hodgkin lymphoma can be cured with first-line therapy, but about 15% of patients have relapsed/refractory disease. The current standard of care for relapsed/refractory Hodgkin lymphoma is chemotherapy followed by autologous stem cell transplantation (SCT), but about half of patients relapse after SCT, Savoldo and co-authors noted.

CD30 is universally expressed by Hodgkin/Reed-Sternberg cells and has proven to be a safe target for novel therapies, such as brentuximab vedotin (Adcetris), which achieves sustained remissions in about a fourth of patients with relapsed/refractory Hodgkin lymphoma. Savoldo and colleagues sought to demonstrate that the same approach for using CAR T-cell therapy to treat B-cell malignancies -- targeting the CD19 antigen -- can be applied to treatment of Hodgkin lymphoma with anti-CD30 CAR T-cell therapy.

Clinical evaluation began with a phase I study with anti-CD30 therapy infused without lymphodepleting conditioning treatment. The therapy proved to be safe but had limited clinical activity.

Investigators continued clinical evaluation of the anti-CD30 therapy with lymphodepletion. A total of 41 patients with relapsed/refractory Hodgkin lymphoma received the genetically modified T cells. All patients had received at least two prior lines of therapy (and as many as 23) and a median of seven prior therapies.

Patients received one of three lymphodepleting regimens: cyclophosphamide-fludarabine, bendamustine alone, or bendamustine-fludarabine. A single infusion of anti-CD30 CAR T cells was administered 2 to 5 days after completion of lymphodepleting therapy. Patients who had stable disease or partial response after the infusion could receive a second infusion.

Of the 37 evaluable patients, 34 received fludarabine conditioning. Two of those patients had attained complete remission prior to CAR T-cell infusion and were not included in the efficacy analysis. The treatment led to objective responses in 23 of 32 (72%) patients, consisting of 19 complete responses and four partial responses. Three additional patients had stable disease.

The authors reported no dose-limiting toxicities associated with the CAR T-cell therapy. Ten patients developed grade 1 CRS, which resolved spontaneously in all cases without tocilizumab (Actemra) or corticosteroids. No patient developed grade >1 CRS.

The most commonly reported grade 3 adverse events were lymphopenia (100%), leukopenia (57%), nonpruritic maculopapular skin rash (48%), neutropenia (48%), and thrombocytopenia (26%).

Investigators are looking at biomarkers and clinical factors that might inform future use of the CD30-targeted therapy by helping to identify characteristics associated with response.

"We've started looking at the products made from the patients, the composition, so that we can anticipate what is the right composition of the product to give each patient," Savoldo told MedPage Today. "We're also looking at intrinsic factors in the tumor and in the tumor microenvironment to determine what other players in the immune system play a role."

The researchers are also exploring use of the CAR T-cell therapy in other CD30-associated diseases, especially poor-prognosis conditions, she added.

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Disclosures

The study was supported by the National Cancer Institute, the Leukemia & Lymphoma Society, and UNC Oncology.

Savoldo disclosed relationships with Tessa Therapeutics, Cell Medica, Bluebird Bio, and Bellicum Pharmaceutical, as well as patent/royalty/intellectual property interests. First author Carlos A. Ramos disclosed relationships with Novartis and Tessa Therapeutics.

Go here to read the rest:

CAR-T Safe, Active in Hodgkin Lymphoma - MedPage Today

Read more